Margus Pooga

Dr. Margus Pooga


Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 1998 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
MPMargus Pooga
Margus Pooga
USUrsel Soomets
Ursel Soomets
MHMattias Hällbrink
Mattias Hällbrink
AVAndres Valkna
Andres Valkna
KSKülliki Saar
Külliki Saar
ULUlo Langel
Ulo Langel

1 December 2001 in Biochimica et Biophysica Acta (BBA) - Biomembranes
Verified
Journal Article
Closed access
MHMattias Hällbrink
Mattias Hällbrink
AFAnders Florén
Anders Florén
AEAnna Elmquist
Anna Elmquist
MPMargus Pooga
Margus Pooga
TBTamas Bartfai
Tamas Bartfai
ULUlo Langel
Ulo Langel

1 July 2000 in Biochimica et Biophysica Acta (BBA) - Biomembranes
Verified
Journal Article
Closed access
USUrsel Soomets
Ursel Soomets
MLMaria Lindgren
Maria Lindgren
XGXavier Gallet
Xavier Gallet
MHMattias Hällbrink
Mattias Hällbrink
AEAnna Elmquist
Anna Elmquist
ULUlo Langel
Ulo Langel

1 March 2012 in Molecular Therapy
Verified
Journal Article
Open access
PDF file
HMHelerin Margus
Helerin Margus
KPKärt Padari
Kärt Padari
MPMargus Pooga
Margus Pooga
Short regulatory oligonucleotides (ONs) have a great therapeutic potential for the modulation of gene expression due to their high specificity and low toxicity. The major obstacles for in vivo clinical applications of ONs are the poor permeability of plasma membrane to nucleic acids and the sensitivity of ONs to enzymatic degradation. Hence, various delivery vehicles have been developed to ensure the transduction of ONs into cells. Among these, the cell-penetrating peptides (CPPs) have gained quickly broadening popularity as promising nonviral transmembrane delivery vectors. For coupling of nucleic acids to CPPs, two distinct strategies may be applied—covalent and noncovalent. The majority of earlier studies have used covalent coupling of CPPs to ONs. However, the number of studies demonstrating very high therapeutic potential of noncovalent complexes of ONs with novel CPP-based delivery vehicles is explosively increasing. In this review, the recent developments in the application of CPP-mediated oligonucleotide delivery by noncovalent strategy will be discussed.

1 October 2004 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
PSPille Säälik
Pille Säälik
AEAnna Elmquist
Anna Elmquist
MHMats Hansen
Mats Hansen
KPKärt Padari
Kärt Padari
KSKülliki Saar
Külliki Saar
MPMargus Pooga
Margus Pooga

18 April 2001 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
MPMargus Pooga
Margus Pooga
CKCecilia Kut
Cecilia Kut
MKMadeleine Kihlmark
Madeleine Kihlmark
MHMattias Hällbrink
Mattias Hällbrink
SFSandra Fernaeus
Sandra Fernaeus
ÜLÜlo Langel
Ülo Langel
Proteins with molecular masses ranging from 30 kDa (green fluorescent protein, GFP) to 150 kDa (monoclonal and polyclonal antibodies) were coupled to the cellular translocating peptide transportan. We studied the ability of the resulting protein–peptide constructs to penetrate into Bowes melanoma, BRL, and COS‐7 cells. After 0.5–3 h incubation with recombinant GFP coupled to transportan, most of the GFP fluorescence was found in intracellular membranes of BRL and COS‐7 cells, which suggests that transportan could internalize covalently linked proteins of about 30 kDa in a folded state. Transportan could internalize covalently coupled molecules of even larger size; that is, avidin and antibodies, (up to 150 kDa). The covalent bond between the transport peptide and its cargo is not obligatory because streptavidin was translocated into the cells within 15 min as a noncovalent complex with biotinylated transportan. Inside the cells, the delivered streptavidin was first located mainly in close proximity to the plasma membrane and was later distributed to the perinuclear region. Most of the internalized streptavidin was confined to vesicular structures, but a significant fraction of the protein was distributed in the cytoplasm. Our data suggest that transportan can deliver proteins and other hydrophilic macromolecules into intact mammalian cells, and this finding demonstrates good potential as powerful cellular delivery vector for scientific and therapeutic purposes.